

**HUMAN GENOME SCIENCES  
LEGAL DEPARTMENT****9410 Key West Avenue  
Rockville, MD 20850****Phone: 301-309-8504****Fax: 301-309-8439****FAX COVER SHEET**

DATE: July 27, 2001 TOTAL NUMBER OF PAGES: 17  
TO: Mr. Gary Kunz  
FAX NO.: 703-308-4556  
PHONE NO.: 301-610-5772  
FROM: Michele Wales  
RE: PF112P2D1 and PF112P2D2  
COMMENTS:

FAX RECEIVED  
JUL 30 2001  
GROUP 1600

OFFICIAL

If you experience any difficulty receiving this transmission,  
please contact Charissa Pittman at 301-610-5762.

The information contained in this facsimile message is information protected by attorney-client and/or the attorney/work product privilege. It is intended only for the use of the individual named above and the privileges are not waived by virtue of this having been sent by facsimile. If the person actually receiving this facsimile or any other reader of the facsimile is not the named recipient or the employee or agent responsible to deliver it to the named recipient, any use, dissemination, distribution or copying of the communication is strictly prohibited. If you have received this communication in error, please immediately notify us by telephone and return the original message to us at the above address via U.S. Postal Service.



**Human Genome Sciences, Inc.**  
Legal Department  
3410 Key West Avenue  
Rockville, MD 20850  
(301) 303-8504 (301) 303-8439 Fax

Michele Wales, Ph.D., J.D.  
Direct dial: 301-610-5772  
Email: Michele\_Wales@HGS1.COM

July 27, 2001

*Via Telefacsimile*  
(17 pages - 703-308-4556)

Mr. Gary Kunz  
U.S. Patent and Trademark Office  
Technology Center 1600  
Washington, DC 20231

**Re:** U.S. Patent Application Serial No.: 09/257,272  
Filed: February 25, 1999  
Inventors: Hu et al.  
For: Vascular Endothelial Growth Factor 2  
Our Ref.: PF112P2D2

-and-

U.S. Patent Application Serial No.: 09/219,442  
Filed: December 23, 1998  
Inventors: Hu et al.  
For: Vascular Endothelial Growth Factor 2  
Our Ref.: PF112P2D1

Dear Gary,

Further to our conversation, attached please find three charts. The first chart lists the cases in which the "new" restriction practice has been used on HGS's cases. The second and third chart outlines the claim structure of the VEGF-2 cases. Previously, when I forwarded one of these latter charts to Brian Stanton, I told him that these cases are not representative of our standard claim set, and in fact, it is more complex than we typically file. However, I felt that the summary and the table simplifies the issues and that we would be willing to submit these charts in all of our cases, to help the Examiners in understanding our claim set.

If you need any further information, please do not hesitate to contact me.

Sincerely yours,

Michele Wales

MMW/ur

**FAX RECEIVED**  
**JUL 30 2001**  
**GROUP 1600**

**R stricted HGS' Cases**

<b>Our Docket No.</b>	<b>Serial No.</b>	<b>Filing Date</b>	<b>Art Unit</b>	<b>Examiner</b>	<b>Stat. Date</b>
PF467	09/325,019	06/03/99	1647	Spector	09/15/01
PF448	09/224,110	02/04/99	1647	Hamud	10/24/01
PF470	09/320,713	05/27/99	1647	Spector	09/21/01
PF155C1	09/345,373	07/01/99	1647	Saoud	11/01/01
PF293D1	09/317,641	05/22/01	1646	Jiang	11/22/01
PF398P1	09/268,311	03/16/99	1646	Kemmerer	11/07/01
PF379	09/580,212	05/26/00	1646	O'Hara	11/22/01
PF293	09/317,641	05/25/99	1646	Jiang	11/22/01
PF346D1	09/360,149	07/26/99	1646	Kemmerer	10/05/01
PF376D1	09/372,154	08/11/99	1652	Nashed	Already Responded
<b>PZ027P1</b>	<b>09/397,945</b>	<b>09/17/99</b>	<b>1631</b>	<b>Borin</b>	<b>08/14/01</b>
PF345P1	09/109,864	07/06/98	1646	Ulm	Already Responded
PF494	09/487,614	1/20/00	1652	Moore	09/02/01
PF503	09/466,829	12/20/99	1647	Turner	12/06/01
PZ021P1	09/334,595	06/17/99	1631	Borin	12/11/01
PF375P1	09/527,236	03/16/00	1646	O'Hara	01/12/02
PZ004P1	09/154,707	09/17/98	1633	Martinell	Already Responded
PF168P2	09/393,696	09/10/99	1647	Bunner	01/16/02
PF200	09/393,023	09/09/99	1646	Kaufman	01/06/02
PF341P1	09/573,986	06/18/00	1646	O'Hara	01/12/01
PF491	09/461,419	12/16/99	1646	O'Hara	01/12/01

Gary,

The three cases in which we already responded, by arguing against the restriction, have been made final and, if possible, we would like them reconsidered once the new policy has been established.

Thanks, Michele